Rivermount VC Fund

Co-founders Deborah Lynch and Ted Powell manage the fund. The firm states its GP group blends 30 years of investment experience with 30 years of biotech operating experience, though it does not specify which partner leads sourcing or investment-committee decisions. Senior consultant Theresa Metz also appears on the team page, but her exact role in deal execution is not detailed.

Rivermount says it seeks early-stage opportunities in high-tech and healthcare for high-net-worth families. The disclosed portfolio is heavily weighted toward therapeutics and medical devices, with positions in RNA therapies, digital PCR, neuromodulation, and diagnostics. The firm targets asset appreciation through technological innovation and does not publicly discuss stage cutoffs, check sizes, or reserve strategies.

Rivermount operates a venture fund alongside Rivermount Management LLC, a consulting entity that provides portfolio management, financial planning, and alternative-investment advice. This dual structure means the firm both deploys capital into its own venture deals and advises the same high-net-worth families on their broader asset allocations.

The firm's website only details direct company investments and does not mention fund-of-fund commitments. Its portfolio list is entirely composed of named operating companies in biotech and healthcare, and there is no reference to allocations to external venture managers.

Yes. The firm's website distinguishes a section labeled 'Portfolio of the Team Before Founding the Fund' that includes Flexus Biosciences, acquired by Bristol Myers Squibb, and Arcus Biosciences, which completed an IPO in 2018. These deals are not part of Rivermount's formal fund vehicle but indicate the principals' prior investment activity.